Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye

NCT06903611 is registered in ClinicalTrials.gov with Cambium Bio Limited as lead sponsor.

NCT NCT06903611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06903611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye
Lead sponsor
Cambium Bio Limited
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2028
Enrollment
475 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye, dry eye disease, dry eye syndromes, dry eyes chronic